Abstract:Screening for novel antibacterial compounds in small molecule libraries has a low success rate. We applied machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimental validation. We first binarized 29,537 compounds according to their growth inhibitory activity (hit rate 0.87%) against the antibiotic-resistant bacterium Burkholderia cenocepacia and described their molecular features with a directed-message passing neural network (D-MPNN). Then, we used the data to train an ML model that achieved a receiver operating characteristic (ROC) score of 0.823 on the test set. Finally, we predicted antibacterial activity in virtual libraries corresponding to 1,614 compounds from the Food and Drug Administration (FDA)-approved list and 224,205 natural products. Hit rates of 26% and 12%, respectively, were obtained when we tested the top-ranked predicted compounds for growth inhibitory activity against B . cenocepacia , which represents at least a 14-fold increase from the previous hit rate. In addition, more than 51% of the predicted antibacterial natural compounds inhibited ESKAPE pathogens showing that predictions expand beyond the organism-specific dataset to a broad range of bacteria. Overall, the developed ML approach can be used for compound prioritization before screening, increasing the typical hit rate of drug discovery. Large-scale screening of chemical libraries can aid in the identification of bioactive lead compounds. However, the effectiveness of screening these libraries is impeded by associated expenses and limited chemical diversity. To address this problem, we trained a machine learning (ml) model with molecular properties of compounds that had antibacterial activity against the antibiotic-resistant bacterium Burkholderia cenocepacia . We then used the ml model to predict antibacterial activity in a library of FDA-approved compounds and an extensive, highly diverse virtual library of natural products, shortlisting compounds that could be further tested for activity in the laboratory. We confirmed the activity of top-ranked compounds against B . cenocepacia and ESKAPE pathogens. This work presents an ml approach that expands high-throughput screening datasets to the in silico identification of small molecules with potential activity and increases the hit rate of drug discovery.

CSEL-BGC: A Bioinformatics Framework Integrating Machine Learning for Defining the Biosynthetic Evolutionary Landscape of Uncharacterized Antibacterial Natural Products

A deep learning genome-mining strategy for biosynthetic gene cluster prediction

Deep-BGCpred: A unified deep learning genome-mining framework for biosynthetic gene cluster prediction

Focused Natural Product Elucidation by Prioritizing High-Throughput Metabolomic Studies with Machine Learning

A Natural Product Chemist's Guide to Unlocking Silent Biosynthetic Gene Clusters

Targeting Bacterial Genomes for Natural Product Discovery

Breaking the Silence: New Strategies for Discovering Novel Natural Products.

Automated, Self-Resistance Gene-Guided, and High-Throughput Genome Mining of Bioactive Natural Products from Streptomyces

Next-generation synthetic biology approaches for the accelerated discovery of microbial natural products

Elucidation of genes enhancing natural product biosynthesis through co-evolution analysis

Combinatorial discovery of antibacterials via a feature-fusion based machine learning workflow

Complete genome sequencing and in silico genome mining reveal the promising metabolic potential in Streptomyces strain CS-7

A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery

Modeling Antibacterial Activity with Machine Learning and Fusion of Chemical Structure Information with Microorganism Metabolic Networks

Discovery of microbial natural products by activation of silent biosynthetic gene clusters

Predicting biological activity from biosynthetic gene clusters using neural networks

Merging chemical ecology with bacterial genome mining for secondary metabolite discovery

Computational Tools for Discovering and Engineering Natural Product Biosynthetic Pathways

Genome mining and prospects for antibiotic discovery

An atlas of bacterial secondary metabolite biosynthesis gene clusters